Background. Human papillomavirus (HPV) vaccination is safe and efficacious in women without human immunodeficiency virus (HIV). Although good immunogenicity has been observed in women living with HIV (WLWH), efficacy data in this population are needed.
Cervical cancer is a major health burden for women, resulting in over 250 000 deaths globally each year [1] . Although low-and middle-income countries bear the greatest burden of disease, with an age-standardized cervical cancer mortality rate of 8.3 per 100 000 population, many women in high-income countries (HIC) also continue to be affected, with a mortality rate of 3.3 per 100 000 [2] . Human papillomavirus (HPV) has been well established as the primary causal agent of cervical cancer, making this cancer a vaccine-preventable disease [3, 4] .
HPV is also the causal agent of genital warts, a widespread problem with a global annual incidence of 195 per 100 000 population [5] . Although genital warts are not life threatening, they are one of the most frequent sexually transmitted infections, resulting in negative quality of life consequences [6, 7] .
Women living with human immunodeficiency virus (HIV) (WLWH) are disproportionately affected by HPV infection and cervical cancer, with HIV infection being an independent risk factor for cervical cancer [8, 9] . WLWH have a 47-53% prevalence of HPV infection, which is approximately double the prevalence among women without HIV (22-29%) [10, 11] . Compared to invasive cervical cancers (ICCs) in women without HIV, ICCs in WLWH have a higher prevalence of oncogenic HPV types other than HPV16 and 18, which appears to be due to higher rates of multiple HPV infection among WLWH [12] . Despite widespread screening programs in HIC, WLWH continue to experience higher and more rapid rates of progression to high-grade cervical dysplasia and ICC than women without HIV. Among North American women, WLWH have an ICC incidence rate of 26 per 100 000 person-years, compared to 6 per 100 000 person-years in women without HIV [13] . WLWH are also more likely to experience larger and more recurrent warts; genital wart incidence was reported as 5.0 per 100 person-years in WLWH compared to 1.3 per 100 person-years in women without HIV [14] .
HPV vaccines exist in bivalent, quadrivalent, and nonavalent formulations. These vaccines have shown a high degree of safety, immunogenicity, and efficacy in HIV-negative populations [15] [16] [17] [18] [19] [20] [21] [22] [23] [24] [25] [26] [27] . HPV vaccine safety and immunogenicity results within populations with HIV appear promising [28] [29] [30] , with data from our cohort showing 94-99% seroconversion and improved peak geometric mean titers (GMTs) in participants with HIV virologic suppression compared to those not suppressed [31] . There has been a prior publication of HPV vaccine efficacy in persons living with HIV [32] but none to date of WLWH with cervical disease endpoints. This analysis assesses the 2-year efficacy of the quadrivalent HPV (qHPV) vaccine in a cohort of WLWH. As no immune correlate of protection for HPV has been established, efficacy findings are critical to better understand how the HPV vaccine performs in individuals with HIV. HPV vaccines are currently offered in HIV-endemic countries without HIV-specific efficacy data to support schedule recommendations for individuals with HIV. As the first report of infection and histological outcomes in WLWH post-HPV vaccination, these findings will inform vaccine rollout for this population globally.
METHODS

Study Population
Girls and WLWH were recruited from 14 HIV clinics across Canada between 2008 and 2012, as described in a previous publication [31] . Eligibility included the following: aged 9 years or older, not pregnant, willing to avoid pregnancy during the vaccination series, and had to have a cervix. Recruited individuals were ineligible if they had received any HPV vaccine, had an allergy to vaccine components, were currently enrolled in a trial of an investigational drug or vaccine, or if a site investigator deemed their health to be exclusionary. Participants, or guardians, provided voluntary informed consent to participate.
Study Design
Participants were asked to attend 8 study visits: 1 screening visit (−3 months) and 7 study visits (months 0/2/6/7/12/18/24) and were to receive 3 doses of qHPV vaccine intramuscularly at months 0/2/6. Pelvic examination was performed on participants who were post-menarchal and sexually active. Cervical cytology and cervicovaginal HPV DNA samples were collected at screening and at months 0/6/12/18/24. Cervical cytology samples were collected using ThinPrep® Pap Test and were classified by Bethesda Criteria at the British Columbia Cancer Agency Cervical Cancer Screening Laboratory. For HPV DNA detection, cervicovaginal samples collected in PreservCyt® were processed and typed for 36 HPV genotypes by Linear array assay (Roche Molecular Systems) [33] . Participants were referred for colposcopies as per regional recommendations. Histological diagnoses were collected from pathology reports of individuals who underwent colposcopy with cervical biopsy and/or endocervical curettage.
Statistical Methods
In this efficacy analysis, newly acquired persistent HPV infection was defined as the detection of the same qHPV type (ie, HPV type protected against by the qHPV vaccine; HPV6/11/16/18) in samples collected at 2 or more consecutive visits (>6 months apart) or detection of qHPV at the last available visit [34] .
The second endpoint was incident cervical intraepithelial neoplasia of grade 2 and higher (CIN2+). Participants considered for this endpoint had to have normal baseline cytology. A third endpoint was incident genital warts and participants had to have no genital warts present at baseline to be considered for this endpoint. Duration of follow-up for the endpoints varies due to the differing inclusion criteria.
Analyses were undertaken in 3 subpopulations. The per-protocol efficacy (PPE) population included those who received all 3 doses of vaccine within 1 year and who had at least 1 follow-up visit including pelvic examination after month 7 post-initial vaccination. Participants had to be naive to the relevant qHPV type at baseline by competitive Luminex immunoassay and Linear array assay (ie, antibody and DNA negative). Case counting for this population began at month 7. A naive to relevant type (NRT) population and an intention-to-treat (ITT) population were also considered. Participants in the NRT population received at least 1 dose of vaccine, attended at least 1 follow-up visit with pelvic examination after day 1, and were naive to the relevant qHPV type at baseline. Participants included in the ITT group received at least one dose of vaccine and attended at least 1 follow-up visit with pelvic examination after day 1. Case counting began on day 1 for participants in the NRT and ITT analyses.
Due to the known safety and efficacy of the qHPV vaccine in the prelicensure trials, it was unethical to perform a placebo-controlled study. However, comparisons were drawn between our cohort and a cohort of women without HIV to provide context for our results. The most suitable group for comparison was that of Muñoz et al (2009), which had a similar median follow-up time of 2.2 years and age range of 24-45 years (median = 35, n = 1911) [18] . In order to improve similarity of our cohort to this comparator group, PPE, NRT, and ITT subpopulations for comparison were created in which participants from our cohort were excluded if they had a history of genital warts, history of cervical disease, or past cervical surgical procedure as these women would have been ineligible for the Muñoz et al study. The comparator group utilized a composite endpoint of persistent qHPV, external genital disease, or cervical disease associated with qHPV types. Results for the same composite endpoint were procured within our vaccinated WLWH to assess differences. The definitions of these endpoints were consistent between studies.
Comparison was also made to unvaccinated WLWH from a previous study, the Canadian Women's HIV Study (CWHS) [10] . CWHS followed 750 WLWH in the pre-HPV vaccine era (1993) (1994) (1995) (1996) (1997) (1998) (1999) (2000) (2001) (2002) and had the same median follow-up time of 2 years, a similar median age of 33 (interquartile range [IQR], 28-38), a similar ethnic makeup, and participants received their care at many of the same clinics across Canada [10] .
RESULTS
In total, 420 girls and women were enrolled in this national observational study. Of those enrolled, 279 women met inclusion criteria for at least 1 subpopulation of this 2-year efficacy analysis; reasons for noninclusion are described in Figure 1 . Baseline characteristics of eligible participants are shown in Table 1 . The median age was 39 years (IQR, 34-45; range, 13-66). Participants were ethnically mixed but predominantly black (41.9%) and white (36.2%). The region of origin was predominantly Canada (50.5%), followed by Africa (33.3%). The median CD4 count at first vaccination was 500 cells/mm 3 (IQR, 380-682), and 69% of participants had HIV plasma viral loads <50 copies/mL. In sum, 266 (95.3%) received all 3 doses of vaccine, 7 (2.5%) received 2 doses, and 6 (2.2%) received 1 dose. At baseline, the most frequently detected HPV types were HPV16 (10.3%), HPV52 (9.1%), and HPV45 (7.1%). Prevalent HPV18 infection was only seen in 5.6% of participants. The vaccine was found to be safe and highly immunogenic within this population, as previously described [31] .
Among women in the ITT group (Table 2) , 11 cases of newly acquired persistent qHPV were observed in 477.7 person-years of follow-up (median follow-up 2 years; IQR, 1.6-2.1). The incidence rate of this endpoint was 2.3 per 100 person-years (95% Figure 1 . Flowchart of study participants. Abbreviations: ITT, intention-to-treat; NRT, naive to relevant type; PPE, per-protocol efficacy; qHPV, quadrivalent human papillomavirus (HPV6/11/16/18). Within the NRT population, the incidence rate of newly acquired persistent qHPV was 1.1 per 100 person-years (95% CI, 0.3-2.5), and the incidence rate of genital warts was 2.1 per 100 person-years (95% CI, 1.0-3.9). All cases of persistent qHPV were due to HPV18. No cases of CIN2+ were observed.
Among 212 women eligible for the PPE population, the incidence rate of newly acquired persistent qHPV was 1.0 per 100 person-years (95% CI, 0.3-2.6). All 4 cases of persistent qHPV were due to HPV18. No cases of qHPV-associated CIN2+ developed among women with normal baseline cytology. There were, however, 2 cases of cytological HSIL, 1 atypical glandular cells (AGC), and 1 atypical squamous cells-cannot exclude HSIL (ASC-H) in women with normal baseline cytology. None of these abnormal cytology results were qHPV-associated. Within the PPE population, the incidence rate of genital warts was 1.0 per 100 person-years (95% CI, 0.3-2.5). Of the 4 genital wart cases, 3 were HPV6 DNA-positive at baseline, and 1 had a history of warts and was HPV6 DNA-positive at the time of wart detection. As such, these newly clinically recognized warts were likely due to preexisting infection.
Although there were too few events of vaccine failure within the PPE group to assess predictors in a statistically robust manner, some trends were observed ( Table 3 It was notable that all 4 cases of breakthrough persistent qHPV in the PPE group were HPV18. In the NRT group, the same 4 cases of HPV18 were seen as well as 1 additional case of HPV18. As this is a statistically unlikely situation given the higher prevalence of HPV16 and 6 in the general population, this finding was further explored. This finding was not due to laboratory contamination as the samples were collected over the span of 1 year, did not undergo HPV DNA testing concurrently, and all negative controls during this year tested negative. Screening and baseline samples from these participants were retested with an HPV18-specific real time PCR assay to determine if these individuals were incorrectly classified as naive to HPV18 at study initiation [35] . The real-time assay revealed that Abbreviations: GMT, geometric mean titer; HIV, human immunodeficiency virus; qHPV, quadrivalent human papillomavirus (HPV6/11/16/18). the 1 individual who was only in the NRT group was infected with HPV18 at screening and thereby did not represent vaccine failure. The sample contained a very low HPV18 copy number, which explains why it was previously negative via the less sensitive Linear array assay. All PPE cases remained classified as naive to HPV18 at baseline with the real-time PCR assay (data not shown). Of the 4 HPV18 cases, 1 was a persistent infection present at 2 consecutive study visits. In the remaining samples, HPV18 was only present in the last available sample.
Comparison to the Muñoz et al cohort of women without HIV [18] showed that the rates of the composite endpoint (ie, vaccine failure) were greater in our cohort of WLWH for the PPE group compared to the HIV-negative vaccinated PPE group (1.2 vs 0.1 per 100 person-years; rate ratio, 11.7 [95% CI, 2.6-52.1]), although not significantly greater when comparing the NRT or ITT groups (NRT rate ratio, 4.1; ITT rate ratio, 1.1) ( Table 4 ). In fact, the composite endpoint rates within our groups of vaccinated WLWH were not different from the HIVnegative placebo group rates (PPE rate ratio, 0.8; NRT rate ratio, 1.0; ITT rate ratio, 0.8).
We also compared the incidence rates of persistent qHPV, CIN2+, and genital warts to a cohort of unvaccinated WLWH from the CWHS conducted in the pre-HPV vaccine era (Table 5 ) [10] . The rate of persistent qHPV is substantially lower among vaccinated WLWH compared to the historical unvaccinated group (2.3 vs 6.0 per 100 person-years). However, the rates of genital warts and CIN2+ do not differ greatly (2.3 vs 2.9 per 100 person-years and 0 vs 1 per 100 person-years, respectively).
DISCUSSION
The fact that our WLWH experienced rates of persistent qHPV and qHPV-related disease similar to those of an HIV-negative placebo group from the literature [18] suggests that WLWH may be at higher risk for vaccine failure than their HIV-negative counterparts. However, the rate of newly acquired persistent qHPV was significantly less than the rate seen in unvaccinated WLWH in the literature [10] , which suggests that although protection is not as complete as that seen in women without HIV, an important benefit appears to be present.
Overall rates of vaccine failure were low within this cohort of WLWH. The fact that 3 out of 4 HPV18 breakthrough infections were cases in which the infection was present at the last available sample and not persistent between 2 study visits does not diminish the relevance of our findings because the definition of breakthrough persistent qHPV infection is consistent with other studies of HPV vaccine efficacy. The lack of any CIN2+ diagnoses thus far is encouraging but not a surprising finding at 2 years of follow-up as CIN2+ usually requires 7-10 years to develop in women without HIV [36] ; however, this remains a promising finding, as median time to CIN2+ diagnosis has been reported to be as short as 3 years in women without HIV [37] . Further follow-up is underway to assess longer-term efficacy of the vaccine within this cohort.
The disparities noted between the median baseline CD4 counts and CD4 nadirs of all PPE cases and noncases suggest that present and historical immune dysfunction may contribute to breakthrough HPV infection and disease as a whole, not solely to HPV18 breakthrough. Higher case numbers are required to properly elucidate this relationship. The fact that a higher incidence of HPV-associated disease is seen in WLWH who have CD4 counts below 350 cells/μL supports the idea that impaired immune functionality caused by HIV may play a role in HPV persistence and disease [38] and that HPV-specific CD4 responses to the vaccine may be deficient in women with breakthrough infection and disease despite overall good immunogenicity in this cohort [31] . Future studies assessing CD4-induced vaccine responses in WLWH would provide valuable insight. Importantly, comparisons between groups of women who experienced vaccine failure and those who did not may evolve as further vaccine failure may occur over time.
STRENGTHS AND LIMITATIONS
To our knowledge, this study is the first report of HPV vaccine efficacy against cervical infection and disease in WLWH, providing valuable insights toward prevention of HPV-associated disease in this population. Study limitations include moderate cohort size with relatively short follow-up time of 2 years, which affected our ability to produce highly precise confidence intervals. This cohort continues to be followed, and future reporting on longer follow-up is forthcoming. Due to the ethical limitation of not using a placebo group, our comparisons utilize comparable published data from an HIV-negative vaccinated cohort [18] and a historical group of WLWH [10] . Partner deposition of HPV could be responsible for the detection of some HPV cases. Recent literature suggests that only approximately 14% of HPV DNA detected in a cohort of Canadian women is due to recent vaginal sex [39] .
CONCLUSIONS
Given the relatively low rate of vaccine failure within the first 2 years of follow-up, paired with a good safety and immunogenicity profile, the HPV vaccine should continue to be offered to a wide age range of WLWH. It is, however, important to recognize that WLWH appear to be at higher risk than women without HIV for acquiring persistent qHPV-related infection and disease despite vaccination against HPV. As a result, regular cervical screening remains important in vaccinated WLWH. Even though the protection may not be as complete, the rate of persistent qHPV is greatly diminished in vaccinated compared to unvaccinated WLWH. Longer-term follow-up will better inform vaccine schedule recommendations for this population. 
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